Table 1.
Baseline characteristic of TESTING participants
| Parameter | Full-dose protocol (N = 262) | Low-dose protocol (N = 241) | Testing for differences | Combined protocols (N = 503) |
|---|---|---|---|---|
| Age | ||||
| N | 262 | 241 | 503 | |
| Mean (SD) | 38.6 (11.1) | 37.2 (10.7) | 0.1537 | 37.9 (10.9) |
| Median (IQR) | 37.2 (29.3; 47.3) | 35.4 (29.0; 45.0) | 36.1 (29.0; 45.9) | |
| Sex | ||||
| Female | 96/262 (36.6%) | 102/241 (42.3%) | 0.1925 | 198/503 (39.4%) |
| Male | 166/262 (63.4%) | 139/241 (57.7%) | 305/503 (60.6%) | |
| Race | ||||
| Caucasian/European | 8/262 (3.1%) | 17/241 (7.1%) | 25/503 (5.0%) | |
| Chinese | 251/262 (95.8%) | 128/241 (53.1%) | 379/503 (75.3%) | |
| South Asian | 0/262 (0.0%) | 63/241 (26.1%) | 63/503 (12.5%) | |
| South-East Asian | 3/262 (1.1%) | 30/241 (12.4%) | <0.0001 | 33/503 (6.6%) |
| Japanese | 0/262 (0.0%) | 1/241 (0.4%) | 1/503 (0.2%) | |
| Other Eastern Asian | 0/262 (0.0%) | 1/241 (0.4%) | 1/503 (0.2%) | |
| Mixed | 0/262 (0.0%) | 1/241 (0.4%) | 1/503 (0.2%) | |
| BMI | ||||
| N | 262 | 237 | 499 | |
| Mean (SD) | 24.33 (4.12) | 25.73 (4.88) | 0.0005 | 24.99 (4.55) |
| Median (IQR) | 23.93 (21.48; 26.22) | 25.10 (22.66; 28.33) | 24.34 (21.87; 27.08) | |
| Smoking history | ||||
| Nonsmoker | 197/262 (75.2%) | 198/241 (82.2%) | 395/503 (78.5%) | |
| Previous smoker | 44/262 (16.8%) | 22/241 (9.1%) | 0.0394 | 66/503 (13.1%) |
| Current smoker | 21/262 (8.0%) | 21/241 (8.7%) | 42/503 (8.3%) | |
| Macrohematuria | 51/262 (19.5%) | 29/241 (12.0%) | 0.0228 | 80/503 (15.9%) |
| Hypertension history | 123/262 (46.9%) | 118/241 (49.0%) | 0.6512 | 241/503 (47.9%) |
| Tonsillectomy history | 2/262 (0.8%) | 1/241 (0.4%) | 0.6122 | 3/503 (0.6%) |
| Past systematic corticosteroid therapy | 8/262 (3.1%) | 20/241 (8.3%) | 0.0104 | 28/503 (5.6%) |
| Past (other) immunosuppressant therapy | 14/262 (5.3%) | 15/241 (6.2%) | 0.6721 | 29/503 (5.8%) |
| Family history of IgA nephropathy | 7/262 (2.7%) | 5/241 (2.1%) | 0.6611 | 12/503 (2.4%) |
| Diabetes mellitus | 4/262 (1.5%) | 13/241 (5.4%) | 0.0165 | 17/503 (3.4%) |
| Coronary heart disease | 5/262 (1.9%) | 2/241 (0.8%) | 0.3023 | 7/503 (1.4%) |
| Stroke | 4/262 (1.5%) | 2/241 (0.8%) | 0.4720 | 6/503 (1.2%) |
| Peptic ulcer | 2/262 (0.8%) | 0/241 (0.0%) | 0.1741 | 2/503 (0.4%) |
| Heart failure | 0/262 (0%) | 0/241 (0%) | 0/503 (0) | |
| eGFR level | ||||
| N | 261 | 241 | 502 | |
| Mean (SD) | 59.19 (23.64) | 66.59 (25.57) | 0.0008 | 62.74 (24.84) |
| Median (IQR) | 55.17 (41.69; 72.36) | 61.53 (44.61; 84.40) | 58.28 (43.09; 78.96) | |
| Urine protein, g/24 h | ||||
| N | 257 | 240 | 497 | |
| Mean (SD) | 2.49 (1.44) | 2.60 (2.06) | 0.4633 | 2.54 (1.76) |
| Median (IQR) | 2.13 (1.42; 2.95) | 2.02 (1.48; 3.05) | 2.10 (1.45; 3.02) | |
| Time since kidney biopsy, months | ||||
| N | 261 | 241 | 502 | |
| Mean (SD) | 12.05 (34.98) | 19.88 (31.11) | 0.0085 | 15.81 (33.38) |
| Median (IQR) | 5.00 (3.00; 8.00) | 6.00 (4.00; 22.00) | 5.00 (4.00; 13.00) | |
| Mesangial hypercellularity | ||||
| M0 | 104/255 (40.8%) | 94/238 (39.5%) | 0.7706 | 198/493 (40.2%) |
| M1 | 151/255 (59.2%) | 144/238 (60.5%) | 295/493 (59.8%) | |
| Segmental glomerulosclerosis | ||||
| S0 | 72/255 (28.2%) | 85/238 (35.7%) | 0.0749 | 157/493 (31.8%) |
| S1 | 183/255 (71.8%) | 153/238 (64.3%) | 336/493 (68.2%) | |
| Endocapillary hypercellularity | ||||
| E0 | 189/262 (72.1%) | 187/241 (77.6%) | 0.1594 | 376/503 (74.8%) |
| E1 | 73/262 (27.9%) | 54/241 (22.4%) | 127/503 (25.2%) | |
| Tubular atrophy/interstitial fibrosis | ||||
| T0 | 94/255 (36.9%) | 147/238 (61.8%) | 241/493 (48.9%) | |
| T1 | 118/255 (46.3%) | 69/238 (29.0%) | <0.0001 | 187/493 (37.9%) |
| T2 | 43/255 (16.9%) | 22/238 (9.2%) | 65/493 (13.2%) |